- Market Capitalization, $K 40,021,864
- Shares Outstanding, K 151,466
- Annual Sales, $ 1,465 M
- Annual Income, $ 380,000 K
- 60-Month Beta 0.73
- Price/Sales 27.23
- Price/Cash Flow 104.89
- Price/Book 17.60
|Period||Period Low||Period High||Performance|
| || |
+5.27 (+2.04%)since 03/12/21
| || |
-20.10 (-7.10%)since 01/12/21
| || |
+100.93 (+62.26%)since 04/09/20
Strong performance in both its Animal Safety and Food Safety segments during the fiscal third quarter pushes Neogen (NEOG) to a 52-week high.
Investor optimism is high on NextGen (NXGN) stock, courtesy of its solid prospects.
PRA Health's (PRAH) remote patient monitoring platform will enable Merck KGaA to offer patients an array of advanced tools to help manage their conditions.
Everbridge (EVBG) gears up to acquire software maker, xMatters to enhance its IT Alerting and Incident Management offerings.
BD's (BDX) $65-million investment in constructing an advanced facility will become integral to the U.S. medical device supply chain.
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Here we discuss five enterprise software companies -- MSFT, ADBE, CDNS, VEEV, and UPLD -- which are well poised to gain from coronavirus crisis triggered spend on digital transformation amid proliferation...
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Veeva (VEEV) could produce exceptional returns because of its solid growth attributes.
Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
|Veeva Systems Inc|
|Franklin Genomic Advancements ETF|
|Ark Genomic Revolution ETF|
|Invesco Focused Discovery Growth ETF|
|DJ Internet Index First Trust|
|Northern Lights IV Large Cap Momentum|
|3rd Resistance Point||271.53|
|2nd Resistance Point||268.61|
|1st Resistance Point||265.83|
|1st Support Level||260.13|
|2nd Support Level||257.21|
|3rd Support Level||254.43|